Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, announces today that it has granted an aggregate of 175,000 stock options at an exercise price of $0.15 per common share, to the President & CEO of the Company.
The options are set to expire five years from the date of grant and are subject to approval of the TSX Venture Exchange. The grant of options is also subject to TSX Venture Exchange acceptance and the terms of Kane Biotech's stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.
Short bursts of exercise can lower dementia risk